Background: Breast cancer is one of the leading cancers in women in the Western world. Cancer treatment, especially chemotherapy, is often associated with physical and psychosocial side effects.
Objective: To improve the quality of life and manage side effects, a new integrative mind-body-medicine group concept for breast cancer patients receiving chemotherapy was developed and pilot tested.
Methods: Breast cancer patients participated in a 66 hours mind-body-medicine group program tailored to the needs of cancer patients during chemotherapy. The program was integrated into standard care encompassing mindfulness training, yoga, moderate exercise, nutrition, complementary self-help strategies, cognitive restructuring, and acupuncture. Quality of life (EORTC QLQ-C30), depression and anxiety (HADS), stress (PSS-10), and fatigue (BFI) were assessed before and after the program, as well as satisfaction and safety. Analyses were carried out on exploratory basis with paired samples t-tests.
Results: Fifty-seven female patients, aged 51.3±10.5 years, with breast cancer diagnoses were enrolled. After completing the program, global EORTC quality of life was improved (D=9.5; 95%-CI=[2.9|16.1]; p=.005), although the EORTC-symptom scales assessing fatigue (D=9.9; 95%-CI=[1|18.8]; p=.030), nausea (D=7.1; 95%- CI=[0.6|13.6]; p=.031), and dyspnea (D=12.5; 95%-CI=[2.9|22.1]; p=.011) were found to be increased. Stress (D=-3.5; 95%-CI=[-5|-2.1]; p=.000), anxiety (D=-3.8; 95%-CI=[-4.9|-2.7]; p=.000) and depression (D=-3.9; 95%-CI=[-4.9|-2.8]; p=.000) were also found to be significantly reduced. Regarding the severity of (D=0.2; 95%- CI=[-0.8|0.5]; p=.644) and the impairment due to fatigue (D=0.1; 95%-CI=[-0.8|0.6]; p=.696), no significant worsening was observed. Patients were satisfied with the program. No serious adverse events were reported.
Conclusion: Breast cancer patients benefit from an integrative mind-body-medicine group program during chemotherapy regarding the quality of life and psychological symptoms. Randomized controlled trials are warranted.
[http://dx.doi.org/10.1016/S0140-6736(15)60692-4] [PMID: 26063472]
[http://dx.doi.org/10.1016/S0140-6736(16)31678-6] [PMID: 27733282]
[http://dx.doi.org/10.1093/annonc/mdw099] [PMID: 26940687]
[http://dx.doi.org/10.1002/14651858.CD010802.pub2] [PMID: 28045199]
[http://dx.doi.org/10.1007/s00404-017-4348-2] [PMID: 28331996]
[http://dx.doi.org/10.1200/JCO.2010.34.0331] [PMID: 22430268]
[http://dx.doi.org/10.1016/j.jpainsymman.2016.08.005] [PMID: 27720794]
[http://dx.doi.org/10.1007/s10549-011-1738-1] [PMID: 21901389]
[http://dx.doi.org/10.1016/j.ejca.2012.10.030] [PMID: 23265707]
[http://dx.doi.org/10.1155/2016/5931816] [PMID: 27019663]
[http://dx.doi.org/10.1177/1534735413492727] [PMID: 23766391]
[http://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x] [PMID: 6880820]
[http://dx.doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N] [PMID: 10091805]
[http://dx.doi.org/10.1159/000431256] [PMID: 26402426]
[http://dx.doi.org/10.1007/s10549-017-4571-3] [PMID: 29139007]
[http://dx.doi.org/10.1200/JCO.2011.36.1154] [PMID: 21825266]